HRP20010039B1 - Derivati kinolina - Google Patents
Derivati kinolinaInfo
- Publication number
- HRP20010039B1 HRP20010039B1 HR20010039A HRP20010039A HRP20010039B1 HR P20010039 B1 HRP20010039 B1 HR P20010039B1 HR 20010039 A HR20010039 A HR 20010039A HR P20010039 A HRP20010039 A HR P20010039A HR P20010039 B1 HRP20010039 B1 HR P20010039B1
- Authority
- HR
- Croatia
- Prior art keywords
- chloro
- fluoro
- hydrogen
- ochxfy
- bromo
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000001246 bromo group Chemical group Br* 0.000 abstract 2
- -1 methoxy, ethoxy Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000002892 organic cations Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spojevi općenite formule (I)naznačeni time, da se u njimaR odabere između metila, etila, n-propila, izo-propila, n-butila, i alila; R' odabere između metila, metoksi, fluoro, kloro, bromo, trifluormetila i OCHxFy, pri čemu x = 0 - 2, y = 1 - 3 uz uvjet da x + y = 3; R" odabere između vodika, fluoro i kloro, uz uvjet da se R" odabere između fluoro i kloro samo kada se R' odabere između fluoro i kloro; R4 odabere između vodika i farmaceutski prihvatljivih anorganskih i organskih kationa; R5 odabere između metoksi, etoksi, kloro, bromo, trifluormetila, OCHxFy i OCH2CHxFy; gdje x = 0 - 2, y = 1 - 3, uz uvjet da x + y = 3; R6 predstavlja vodik; ili R5 i R6 zajedno označuju metilendioksi; i bilo koji njihov tautomer. Patent sadrži još 17 patentnih zahtjeva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
| PCT/SE1999/001270 WO2000003991A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20010039A2 HRP20010039A2 (en) | 2001-12-31 |
| HRP20010039B1 true HRP20010039B1 (hr) | 2009-04-30 |
Family
ID=20412093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010039A HRP20010039B1 (hr) | 1998-07-15 | 2001-01-12 | Derivati kinolina |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1095021B1 (hr) |
| JP (1) | JP4045070B2 (hr) |
| KR (1) | KR100516382B1 (hr) |
| CN (1) | CN1157378C (hr) |
| AP (1) | AP1366A (hr) |
| AT (1) | ATE250036T1 (hr) |
| AU (1) | AU751103B2 (hr) |
| BR (1) | BR9912109B1 (hr) |
| CA (1) | CA2336968C (hr) |
| CZ (1) | CZ300229B6 (hr) |
| DE (1) | DE69911415T2 (hr) |
| DK (1) | DK1095021T3 (hr) |
| EE (1) | EE04673B1 (hr) |
| ES (1) | ES2205854T3 (hr) |
| HK (1) | HK1035715A1 (hr) |
| HR (1) | HRP20010039B1 (hr) |
| HU (1) | HU229427B1 (hr) |
| ID (1) | ID27423A (hr) |
| IL (2) | IL140346A0 (hr) |
| IS (1) | IS2208B (hr) |
| ME (1) | MEP57408A (hr) |
| NO (1) | NO317601B1 (hr) |
| NZ (1) | NZ508923A (hr) |
| OA (1) | OA11906A (hr) |
| PL (1) | PL199783B1 (hr) |
| PT (1) | PT1095021E (hr) |
| RS (1) | RS50128B (hr) |
| RU (1) | RU2213733C2 (hr) |
| SE (1) | SE9802549D0 (hr) |
| TR (1) | TR200100087T2 (hr) |
| UA (1) | UA64791C2 (hr) |
| WO (1) | WO2000003991A1 (hr) |
| ZA (1) | ZA200007593B (hr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51019B (sr) * | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| TW200410671A (en) * | 2002-06-05 | 2004-07-01 | Inst Med Molecular Design Inc | Medicines for inhibiting the activation of AP-1 |
| CA2488979A1 (en) * | 2002-06-11 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of neurodegenerative diseases |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| ZA200810790B (en) | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
| WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DK2234485T3 (da) | 2007-12-20 | 2014-02-10 | Teva Pharma | Stabile laquinimod-præparater |
| CN104311486A (zh) | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DK2458992T3 (en) | 2009-07-30 | 2016-02-08 | Teva Pharma | Treatment of crohn's disease with laquinimod |
| ES2586843T3 (es) | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| AU2011223692A1 (en) | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
| KR20130014523A (ko) | 2010-03-03 | 2013-02-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 |
| NZ606587A (en) | 2010-07-09 | 2015-03-27 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| WO2012025239A1 (en) * | 2010-08-27 | 2012-03-01 | Grünenthal GmbH | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| BR112013007850A2 (pt) * | 2010-10-14 | 2016-06-07 | Immunahr Ab | 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
| BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
| BR112014020372A8 (pt) | 2012-02-16 | 2018-01-23 | Teva Pharma | n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| JP5868839B2 (ja) | 2012-12-27 | 2016-02-24 | 三菱重工業株式会社 | チャー払出管 |
| SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| CA2945978A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
| KR102533033B1 (ko) | 2014-09-23 | 2023-05-15 | 액티브 바이오테크 에이비 | 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 |
| US10300053B2 (en) | 2014-11-19 | 2019-05-28 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| IL295780A (en) | 2020-03-03 | 2022-10-01 | Active Biotech Ab | Tesquinimov or a pharmaceutically acceptable salt thereof for use in combination therapy |
| KR20230043916A (ko) | 2020-07-23 | 2023-03-31 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질 |
| EP4277628A1 (en) | 2021-01-18 | 2023-11-22 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| WO2022248401A1 (en) | 2021-05-25 | 2022-12-01 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
| KR20240029029A (ko) | 2021-07-02 | 2024-03-05 | 액티브 바이오테크 에이비 | 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0059698A1 (en) * | 1981-03-03 | 1982-09-08 | Ab Leo | Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith |
| WO1992018483A1 (en) * | 1991-04-22 | 1992-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1993006829A1 (en) * | 1991-10-09 | 1993-04-15 | Kabi Pharmacia Ab | New use of substituted quinoline carboxamide |
| WO1993019756A1 (en) * | 1992-04-06 | 1993-10-14 | Kabi Pharmacia Ab | The use of quinoline-3-carboxamide compounds for treatment of diabetes |
| WO1995024195A1 (en) * | 1994-03-10 | 1995-09-14 | Pharmacia & Upjohn Ab | New use of quinoline-3-carboxamide compounds |
| WO1995024395A1 (en) * | 1994-03-07 | 1995-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline derivatives as immunomodulators |
| WO1995024196A1 (en) * | 1994-03-10 | 1995-09-14 | Pharmacia & Upjohn Ab | New use of quinoline-3-carboxamide compounds |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
-
1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/xx unknown
-
1999
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Application Discontinuation
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active IP Right Cessation
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 ME MEP-574/08A patent/MEP57408A/hr unknown
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
-
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
-
2001
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation
- 2001-01-12 HR HR20010039A patent/HRP20010039B1/hr not_active IP Right Cessation
- 2001-07-10 HK HK01104765A patent/HK1035715A1/xx not_active IP Right Cessation
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0059698A1 (en) * | 1981-03-03 | 1982-09-08 | Ab Leo | Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith |
| WO1992018483A1 (en) * | 1991-04-22 | 1992-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1993006829A1 (en) * | 1991-10-09 | 1993-04-15 | Kabi Pharmacia Ab | New use of substituted quinoline carboxamide |
| WO1993019756A1 (en) * | 1992-04-06 | 1993-10-14 | Kabi Pharmacia Ab | The use of quinoline-3-carboxamide compounds for treatment of diabetes |
| WO1995024395A1 (en) * | 1994-03-07 | 1995-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline derivatives as immunomodulators |
| WO1995024195A1 (en) * | 1994-03-10 | 1995-09-14 | Pharmacia & Upjohn Ab | New use of quinoline-3-carboxamide compounds |
| WO1995024196A1 (en) * | 1994-03-10 | 1995-09-14 | Pharmacia & Upjohn Ab | New use of quinoline-3-carboxamide compounds |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20010039B1 (hr) | Derivati kinolina | |
| HRP20000726B1 (hr) | Derivati kinolina | |
| CA2298033A1 (en) | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | |
| GR3036887T3 (en) | Meta-substituted phenylene sulphonamide derivatives | |
| CA2205274A1 (en) | Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones | |
| YU35697A (en) | Substituted 6,6-hetero-bicyclic derivatives | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| RS51019B (sr) | Lekovi za lečenje malignih tumora | |
| DE69329727D1 (de) | Neue imidazol derivate, ihre herstellung und therapeutische verwendung | |
| NZ503912A (en) | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists | |
| ES2122258T3 (es) | 4-azaesteroides 15 sustituidos. | |
| IE872773L (en) | 4,5-DIHYDRO and 4,5,6,7-TETRAHYDROPYRAZOLO£1.5-a|PYRIMIDINES | |
| NO20001585L (no) | Orale sammensetninger av levosimendan | |
| SE8503415L (sv) | Nya isoindolinylalkylpiperaziner och farmaceutiska kompositioner innehallande desamma | |
| MX9204179A (es) | Derivados de imidazo(2,1-b)benzotiazola-3-acetamida, su preparacion y su aplicacion en terapeutica. | |
| DE69719974D1 (de) | Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| AU2001261707A1 (en) | Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives | |
| ATE179977T1 (de) | Herbizide pyridinverbindungen | |
| JPS57163368A (en) | 4-aryloxy-1,2,3,4-tetrahydroisoquinoline and intermediate | |
| DK0625982T3 (da) | 4-Oxo- og 4H-imidazo(5,1-c)(1,4)benzoxaziner anvendelige som benzodiazepinreceptor-bindemidler | |
| RS50791B (sr) | Farmaceutske kombinacije zasnovane na derivatima piridoindolona | |
| EP1319658A4 (en) | IMIDAZOLE DERIVATIVES OR THEIR SALTS | |
| YU200791A (sh) | Trifluorometil 1-karba (1-detia) cefemi | |
| FI961793A (fi) | Muistia parantavina aineina käyttökelpoiset 3-aryyli-4-alkyyli- ja 4,5-dialkyyli 4H-1,2,4-triatsolit | |
| FI914138A (fi) | Laekemedel, vilka innehaoller substituerade 2-cyklohexenderivat och deras anvaendning vid vaord av sjukdomar. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20170614 Year of fee payment: 19 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20180714 |